Darrell N. Kotton, MD is the founding director of the Center for Regenerative Medicine of Boston University and Boston Medical Center. He is a physician-scientist with attending physician duties in pulmonary and critical care medicine at Boston Medical Center and is the David C. Seldin Professor in the department of medicine and in the department of pathology and laboratory medicine at the Boston University Chobanian and Avedesian School of Medicine. Dr. Kotton is an Allen Distinguished Investigator, a Paul G. Allen Frontiers Group advised program of the Paul G. Allen Family Foundation. He is also an elected member of the American Society of Clinical Investigators and the Association of American Physicians. He leads a basic research laboratory, funded continuously by the NIH since 2004, focused on lung regeneration and stem cell biology, and he serves on the NIH’s National Heart Lung and Blood Institute’s Board of External Experts. He is the recipient of the American Thoracic Society’s “Recognition Award for Scientific Accomplishments” (2018), the AAMC inaugural national “Research Resources Sharing Award” (2017), the Alpha-1 Foundation’s “Researcher of the Year” (2013) and “Shillelagh” (2010) Awards, Boston University’s Graduate Medical Sciences Educator of the Year Award (2018), and the Robert Dawes Evans Senior Research Mentor Award from Boston University.
Expertise: Stem Cell Biology; iPS cells; Reprogramming; Gene Therapy; Lung Developmental Biology.
Diversity, Equity, Inclusion and Accessibility
I moved to the United States as an immigrant at age 10 years, an experience that continues to inspire a personal appreciation for the importance of fostering inclusivity. My medical training has further instilled in me a desire to help augment diversity, equity, and inclusion (DEI) in every aspect of academic medicine, particularly amongst the trainees and mentors who will serve as role models for current and future generations of scientists, physicians, and physician-scientists. In caring for patients, I have witnessed first-hand the detrimental impacts on health that arise when vulnerable populations are not given equal access to care.
In my role as an educator and Center Director I am fully committed to fostering a training environment and campus that prioritizes diversity, equity, and inclusion (DEI). I serve as a Principal Investigator (PI) or co-PI of 3 training grants at Boston University: our Pulmonary Biology T32, our TL1 Regenerative Medicine Training Program, and an R38 training program focused on Promoting Research in Internal Medicine Residency (PRIMER), and each of these programs has an outstanding track record of high enrollment of trainees from historically under-represented groups (URGs) in biomedical research. I thus consider it a major priority to train a diverse research investigator workforce that will become our future scientists and physicians. For example, 50% of graduate students currently enrolled in our TL1 Regenerative Medicine Training Program are from groups traditionally under-represented in academic medicine. In addition, this past year we significantly augmented high touch interactions with potential candidates for campus training programs, by increasing social media presence and contacts with outside pre-doctoral student candidates at national meetings attended by those interested in seeking graduate school training. For example, our TL1 leaders participated in initiatives for engagement with students at virtual meetings for the Annual Biomedical Research Conference for Minority Students (ABRCMS) and Society for Advancement of Chicanos/Hispanics and Native Americans in Science—Diversity in STEM (SACNAS). I have also worked hard to raise funds to support trainees from URGs who enroll in Boston University’s PREP program, a year-long preparatory program for recent bachelor’s degree recipients who are from URGs and seek entry into competitive PhD training programs. Our Center for Regenerative Medicine today represents a warm, welcoming environment to all, and our Center features an “anti-racism” committee and a small library of books focused on fostering DEI and combatting racism, a topic frequently discussed at our faculty meetings as well as at our weekly lab meetings.
In summary I am committed to fostering diversity, equity, and inclusion in my personal and professional life.
Center for Regenerative Medicine
Boston University Chobanian & Avedisian School of Medicine
Pathology & Laboratory Medicine
Framingham Heart Study
Evans Center for Interdisciplinary Biomedical Research
Genome Science Institute
Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
Modeling Chronic obstructive pulmonary disease (COPD) using human iPSC in vitro
12/16/2019 - 12/16/2026 (PI)AstraZeneca AB
Air pollution disrupts Inflammasome Regulation in HEart And Lung Total Health (AIRHEALTH)
08/01/2021 - 07/31/2026 (Multi-PI)
PI: Darrell Nelson Kotton, MDStanford University NIH NHLBI1P01HL152953-01A1
Biology of the Lung: A Multidisciplinary Program
07/01/2021 - 06/30/2026 (Multi-PI)
PI: Darrell Nelson Kotton, MDNIH/National Heart, Lung, and Blood Institute5T32HL007035-47
NRSA Training Core
04/15/2020 - 03/31/2025 (PI)NIH/National Center for Advancing Translational Sciences5TL1TR001410-07
Engineering Branching Networks Through Synthetic Turing Morphogen Circuits
12/10/2021 - 12/09/2024 (Multi-PI)
PI: Darrell Nelson Kotton, MDAllen Institute d/b/a The Paul G. Allen Frontiers Group
Developing a patient-specific organoid model of pulmonary fibrosis using iPSCs
12/15/2020 - 11/30/2024 (PI)NIH/National Heart, Lung, and Blood Institute5U01HL152976-02
Generation of human alveolar epithelial type I cells from pluripotent stem cells
06/01/2021 - 05/31/2024 (Key Person / Mentor)NIH/National Heart, Lung, and Blood Institute5F31HL158193-02
Characterization of iPSC-derived alveolar epithelial type II cells
12/21/2018 - 12/31/2023 (PI)Novartis Institutes for BioMedical Research
Preparing human lung cells and organoids able to model human responses to respiratory infections and ready to predict effective therapeutics
11/01/2021 - 10/31/2023 (PI)Good Ventures
IDEAL2.0: iPSC Disease Modeling and Drug Screening
01/01/2022 - 06/30/2023 (PI)Bristol-Myers Squibb
Showing 10 of 69 results.
Show All Results
Showing 10 of 90 results.
Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 134 results.
Werder RB, Liu T, Abo KM, Lindstrom-Vautrin J, Villacorta-Martin C, Huang J, Hinds A, Boyer N, Bullitt E, Liesa M, Silverman EK, Kotton DN, Cho MH, Zhou X, Wilson AA. CRISPR interference interrogation of COPD GWAS genes reveals the functional significance of desmoplakin in iPSC-derived alveolar epithelial cells. Sci Adv. 2022 Jul 15; 8(28):eabo6566.View Related Profiles. PMID: 35857525; PMCID: PMC9278866; DOI: 10.1126/sciadv.abo6566;
Hume AJ, Heiden B, Olejnik J, Suder EL, Ross S, Scoon WA, Bullitt E, Ericsson M, White MR, Turcinovic J, Thao TTN, Hekman RM, Kaserman JE, Huang J, Alysandratos KD, Toth GE, Jakab F, Kotton DN, Wilson AA, Emili A, Thiel V, Connor JH, Kemenesi G, Cifuentes D, Mühlberger E. Correction: Recombinant Lloviu virus as a tool to study viral replication and host responses. PLoS Pathog. 2022 Jun; 18(6):e1010659.View Related Profiles. PMID: 35749346; PMCID: PMC9231773; DOI: 10.1371/journal.ppat.1010659;
Berical A, Beermann ML, Suzuki S, LeSuer J, Matte T, Davis B, Kotton D, Hawkins F. Generation of Airway Epithelial Cell Air-Liquid Interface Cultures from Human Pluripotent Stem Cells. J Vis Exp. 2022 Jun 14; (184).View Related Profiles. PMID: 35781291
Werder RB, Huang J, Abo KM, Hix OT, Minakin K, Alysandratos KD, Merritt C, Berthiaume K, Alber AB, Burgess CL, Kotton DN, Wilson AA. Generating 3D Spheres and 2D Air-Liquid Interface Cultures of Human Induced Pluripotent Stem Cell-Derived Type 2 Alveolar Epithelial Cells. J Vis Exp. 2022 Apr 15; (182).View Related Profiles. PMID: 35499347
Basil MC, Cardenas-Diaz FL, Kathiriya JJ, Morley MP, Carl J, Brumwell AN, Katzen J, Slovik KJ, Babu A, Zhou S, Kremp MM, McCauley KB, Li S, Planer JD, Hussain SS, Liu X, Windmueller R, Ying Y, Stewart KM, Oyster M, Christie JD, Diamond JM, Engelhardt JF, Cantu E, Rowe SM, Kotton DN, Chapman HA, Morrisey EE. Human distal airways contain a multipotent secretory cell that can regenerate alveoli. Nature. 2022 Apr; 604(7904):120-126. PMID: 35355013; PMCID: PMC9297319; DOI: 10.1038/s41586-022-04552-0;
Abo KM, Sainz de Aja J, Lindstrom-Vautrin J, Alysandratos KD, Richards A, Garcia-de-Alba C, Huang J, Hix OT, Werder RB, Bullitt E, Hinds A, Falconer I, Villacorta-Martin C, Jaenisch R, Kim CF, Kotton DN, Wilson AA. Air-liquid interface culture promotes maturation and allows environmental exposure of pluripotent stem cell-derived alveolar epithelium. JCI Insight. 2022 Mar 22; 7(6).View Related Profiles. PMID: 35315362; PMCID: PMC8986076; DOI: 10.1172/jci.insight.155589;
Gil CH, Chakraborty D, Vieira CP, Prasain N, Calzi SL, Fortmann SD, Hu P, Banno K, Jamal M, Huang C, Sielski MS, Lin Y, Huang X, Dupont MD, Floyd JL, Prasad R, Longhini ALF, McGill TJ, Chung HM, Murphy MP, Kotton DN, Boulton ME, Yoder MC, Grant MB. Specific mesoderm subset derived from human pluripotent stem cells ameliorates microvascular pathology in type 2 diabetic mice. Sci Adv. 2022 Mar 04; 8(9):eabm5559. PMID: 35245116; PMCID: PMC8896785; DOI: 10.1126/sciadv.abm5559;
Wang SW, Herriges MJ, Hurley K, Kotton DN, Klein AM. CoSpar identifies early cell fate biases from single-cell transcriptomic and lineage information. Nat Biotechnol. 2022 Jul; 40(7):1066-1074.View Related Profiles. PMID: 35190690
Na E, Allen E, Baird LA, Odom CV, Korkmaz FT, Shenoy AT, Matschulat AM, Jones MR, Kotton DN, Mizgerd JP, Varelas X, Traber KE, Quinton LJ. Epithelial LIF signaling limits apoptosis and lung injury during bacterial pneumonia. Am J Physiol Lung Cell Mol Physiol. 2022 Apr 01; 322(4):L550-L563.View Related Profiles. PMID: 35137631; PMCID: PMC8957336; DOI: 10.1152/ajplung.00325.2021;
Miorin L, Mire CE, Ranjbar S, Hume AJ, Huang J, Crossland NA, White KM, Laporte M, Kehrer T, Haridas V, Moreno E, Nambu A, Jangra S, Cupic A, Dejosez M, Abo KA, Tseng AE, Werder RB, Rathnasinghe R, Mutetwa T, Ramos I, de Aja JS, de Alba Rivas CG, Schotsaert M, Corley RB, Falvo JV, Fernandez-Sesma A, Kim C, Rossignol JF, Wilson AA, Zwaka T, Kotton DN, Mühlberger E, García-Sastre A, Goldfeld AE. The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters. bioRxiv. 2022 Feb 09.View Related Profiles. PMID: 35169796; PMCID: PMC8845418; DOI: 10.1101/2022.02.08.479634;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
2020 Association of American Physicians:
AAP, Elected Member
2018 American Thoracic Society:
Research Achievement Award
2018 Boston University, Graduate Medical Sciences:
Educator of the Year Award
2017 Association of American Medical Colleges:
Inaugural Research Resources Sharing Award
2016 David C. Seldin Endowed Professor of Medicine (Inaugural)
2014 Boston Univ. Dept. of Medicine:
Robert Dawes Evans Senior Research Mentor Award
2013 Alpha-1 Foundation:
Researcher of the Year Award
2010 American Society of Clinical Investigation, Elected Member
2009 Founding Director, Center for Regenerative Medicine (CReM) of Boston University and BMC
2007 Boston University Pulmonary Center:
L. Jack Faling Award for Excellence in Teaching
2001 Massachusetts Thoracic Society, 1st Place, Science Research Award
2001 Boston University School of Medicine:
Evans Days Research Award, 1st Runner Up
1999 Boston University Department of Medicine:
Fellow of the Year Award
1997 University of Pennsylvania School of Medicine:
Penn Pearls Teaching Award
1990-1994 Washington University School of Medicine Class President
1990 Washington University School of Medicine:
Distinguished Student Scholarship Award
1989 University of Pennsylvania:
Phi Beta Kappa
1985 University of Pennsylvania:
Benjamin Franklin Scholar
Available to Mentor as: (Review Mentor Role Definitions)
I have experience and success mentoring and preparing trainees for careers as independently funded basic science researchers. I serve as the founding Director of the Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center, and my laboratory has worked since 2004 in the field of pulmonary stem cell biology, regenerative medicine, and gene therapy. Fostering the careers of the next generation of academic medicine researchers and leaders is a top priority for me, and a mission I care about deeply: I have been the PI of a TL1 Training grant in Regenerative Medicine and I became the Co-PI of our campus's T32 Training grant in Lung Biology. I am also Co-PI of our campus’s R38 training program for medical residents interested in research training (PRIMER). I am myself a graduate of our T32 pulmonary training program and a product of the NHLBI’s K08 award program. Thus, I am personally familiar with the NIH’s training mechanisms, both as a trainee, mentor, and now program leader.
Research / Scholarly Mentor